OPEN END TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 18:41:06 17/05/2024 BST | ||
| 15.82 EUR | +2.79% |
|
| Current month | +36.14% | ||
| 1 month | +35.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 15.82 | +2.79% |
| 16/05/24 | 15.39 | +0.59% |
| 15/05/24 | 15.3 | +8.36% |
| 14/05/24 | 14.12 | -2.28% |
| 13/05/24 | 14.45 | +4.48% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 06:41 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KG28VR |
| ISIN | DE000KG28VR2 |
| Date issued | 16/05/2022 |
| Strike | 274.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.83 € |
|---|---|
| Lowest since issue | 1.31 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
